160 related articles for article (PubMed ID: 9327247)
41. [Burkholderia cepacia bacteremia: a prospective analysis of 33 episodes].
Pinilla MI; Cobos-Trigueros N; Soriano Á; Martínez JA; Zboromyrska Y; Almela M; Mensa J
Rev Esp Quimioter; 2011 Dec; 24(4):209-12. PubMed ID: 22173191
[TBL] [Abstract][Full Text] [Related]
42. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
43. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013).
Flamm RK; Castanheira M; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):352-355. PubMed ID: 27112832
[TBL] [Abstract][Full Text] [Related]
44. Burkholderia cepacia infections in cystic fibrosis.
Burns JL; Saiman L
Pediatr Infect Dis J; 1999 Feb; 18(2):155-6. PubMed ID: 10048690
[No Abstract] [Full Text] [Related]
45. Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance.
Dizbay M; Tunccan OG; Sezer BE; Aktas F; Arman D
J Infect Dev Ctries; 2009 May; 3(4):273-7. PubMed ID: 19759490
[TBL] [Abstract][Full Text] [Related]
46. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.
Mayer I; Nagy E
J Antimicrob Chemother; 1999 May; 43(5):651-7. PubMed ID: 10382886
[TBL] [Abstract][Full Text] [Related]
47. [Urinary infection. I. Comparative in vitro activities of several antibiotic drugs against Gram-negative bacteria].
Giachino F; Allocco A; Tuninetti L; Tullio V; Cuffini AM; Carlone NA
G Batteriol Virol Immunol; 1992 Jan-1993 Dec; 85(1-12):55-67. PubMed ID: 7498617
[TBL] [Abstract][Full Text] [Related]
48. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
49. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
[TBL] [Abstract][Full Text] [Related]
50. Sensitization of Burkholderia cepacia to antibiotics by cationic drugs.
Rajyaguru JM; Muszynski MJ
J Antimicrob Chemother; 1998 Feb; 41(2):277-80. PubMed ID: 9533472
[TBL] [Abstract][Full Text] [Related]
51. Synergistic interactions of ciprofloxacin and extended spectrum beta-lactams or aminoglycosides against Acinetobacter calcoaceticus ss. anitratus.
Chow AW; Wong J; Bartlett KH
Diagn Microbiol Infect Dis; 1988 Apr; 9(4):213-7. PubMed ID: 3180706
[TBL] [Abstract][Full Text] [Related]
52. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
[TBL] [Abstract][Full Text] [Related]
53. Dactimicin, a new aminoglycoside: in vitro activity, post-antibiotic effect and interaction with other antibiotics.
Paglia P; Molinari G; Pesce A; Debbia EA
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):639-43. PubMed ID: 2506028
[TBL] [Abstract][Full Text] [Related]
54. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa.
Oie S; Uematsu T; Sawa A; Mizuno H; Tomita M; Ishida S; Okano Y; Kamiya A
J Antimicrob Chemother; 2003 Dec; 52(6):911-4. PubMed ID: 14585851
[TBL] [Abstract][Full Text] [Related]
55. In-vitro susceptibility of clinical isolates of Serratia species to antimicrobial agents.
Sofianou D; Proya E; Kondodimou A
J Chemother; 1990 Apr; 2(2):79-81. PubMed ID: 2362189
[TBL] [Abstract][Full Text] [Related]
56. Association of resistance to trimethoprim/sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia.
Rajyaguru JM; Muszynski MJ
J Antimicrob Chemother; 1997 Dec; 40(6):803-9. PubMed ID: 9462431
[TBL] [Abstract][Full Text] [Related]
57. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
58. Brevundimonas vesicularis bacteremia resistant to trimethoprim-sulfamethoxazole and ceftazidime in a tertiary hospital in southern Taiwan.
Zhang CC; Hsu HJ; Li CM
J Microbiol Immunol Infect; 2012 Dec; 45(6):448-52. PubMed ID: 22516745
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
Peeters E; Nelis HJ; Coenye T
J Antimicrob Chemother; 2009 Oct; 64(4):801-9. PubMed ID: 19633000
[TBL] [Abstract][Full Text] [Related]
60. Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.
Chow AW; Wong J; Bartlett KH
Antimicrob Agents Chemother; 1988 May; 32(5):782-4. PubMed ID: 3395107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
